FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL		
OMB	3235-	
Number:	0104	
Estimated average		
burden hours pe	er	
response	0.5	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print of Type Responses)	<u> </u>							
1. Name and Address of Reportin Person *	State	2. Date of Event Requestatement		3. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD]				
TRAVERSA SERGIO		onth/Day/Year)						
(Last) (First) (Mic C/O RELMADA THERAPEUTICS, INC., 540 FIFTH AVENUE, 14TH FL	ddle)	01/06/2015		erson(s) to l	all applicable)	Filed(Mc	5. If Amendment, Date Original Filed(Month/Day/Year)	
(Street) NEW YORK, NY 10036				le below)	below) xecutive Office	6. Indivi Filing(Cl _X_ Form	idual or Joint/Group neck Applicable Line) filed by One Reporting Person filed by More than One Person	
(City) (State) (Z	Zip)	Tal	ole I - Non	-Derivat	ive Securitie	es Beneficially	y Owned	
1.Title of Security (Instr. 4)		2. Am Benef (Instr.		ecurities ned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership Instr. 5)		
Common Stock		497	,708		D			
required to number.	rho respond o respond u	to the colled nless the for	ction of inf m display	ormation s a curre	contained in ntly valid OM	this form are IB control		
Table II - Derivative	Securities B	eneficially Ow				<u> </u>		
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable at Expiration Date (Month/Day/Year)		Date	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		Conversion or Exercise Price of	Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount o Number o Shares	*	Security: Direct (D) or Indirect (I) (Instr. 5)		
Options	(1)	07/10/2022	Common Stock	677,962	\$ 0.8	D		
Options	<u>(2)</u>	09/30/2023	Common Stock	665,750	\$ 0.8	D		

Reporting Owners

Reporting Owner Name / Address		Relationships			
		10% Owner	Officer	Other	
TRAVERSA SERGIO C/O RELMADA THERAPEUTICS, INC. 546 FIFTH AVENUE, 14TH FLOOR NEW YORK, NY 10036	X		Chief Executive Officer		

Signatures

/s/ Sergio Traversa	01/16/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - The options were granted on July 10, 2012 (the "Grant Date"). The stock options vest on the Grant Date based on the following vesting
- (1) schedule: 25% of the options vest upon the Grant Date and the remaining 75% of the options, vest in equal quarterly increments over the next four (4) years, so that the last set of options shall vest in July 2016.
 - The options were granted on September 30, 2013 (the "Grant Date"). The stock options vest on the Grant Date based on the following
- (2) vesting schedule: 25% of the Options shall vest the Grant Date and the remaining 75% of the Options, shall vest in equal quarterly increments over the next four (4) years, so that the last set of options shall vest in September 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.